September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Subcutaneous IL-18 administration does not inhibit laser CNV in mice
Author Affiliations & Notes
  • Tetsuhiro Yasuma
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Reo Yasuma
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
    Department of Ophthalmology, Nagoya University, Nagoya, Japan
  • Bradley D Gelfand
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Nagaraj Kerur
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Ana Bastos-Carvalho
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Younghee Kim
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Charles B Wright
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Jayakrishna Ambati
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Footnotes
    Commercial Relationships   Tetsuhiro Yasuma, Fight for Sight (F); Reo Yasuma, None; Bradley Gelfand, American Heart Association (F), International Retinal Research Foundation (F); Nagaraj Kerur, None; Ana Bastos-Carvalho, None; Younghee Kim, None; Charles Wright, None; Jayakrishna Ambati, Allergan (R), Inflammasome Therapeutics (I), Inflammasome Therapeutics (S), iVeena Delivery Systems (I), iVeena Delivery Systems (P), iVeena Delivery Systems (S), iVeena Holdings (I), iVeena Holdings (P), iVeena Holdings (S), iVeena Pharmaceuticals (I), iVeena Pharmaceuticals (P), iVeena Pharmaceuticals (S), Olix Pharmaceuticals (F), University of Kentucky (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4518. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tetsuhiro Yasuma, Reo Yasuma, Bradley D Gelfand, Nagaraj Kerur, Ana Bastos-Carvalho, Younghee Kim, Charles B Wright, Jayakrishna Ambati; Subcutaneous IL-18 administration does not inhibit laser CNV in mice. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4518.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Choroidal neovascularization (CNV) is a leading cause of legal blindness among the elderly. Activation of inflammatory process underlies development and progression of CNV. We previously demonstrated that intravitreous administration of the inflammatory cytokine IL-18 did not affect CNV. Anti-angiogenic activity was previously reported by subcutaneous administration of IL-18 manufactured by GlaxoSmithKline to mice, a different source and route from our prior studies. Here, we retested the effects of IL-18 on CNV using recombinant IL-18 from GlaxoSmithKline delivered by subcutaneous injection.

Methods : IL-18 was obtained from GlaxoSmithKline (the same lot as previously reported to exhibit anti-angiogenic activity). To induced CNV model, laser photocoagulation (532nm, 180mW, 0.1sec) was performed in male C57BL/6J mice. Subcutaneous injections of IL-18 or vehicle control were performed before and after laser treatment, in four dosing schemes. Seven days after laser treatment, CNV formation in the laser-burn area was visualized by fluorescein-conjugated isolectin B4, and analyzed by confocal microscopy.

Results : None of four administration protocols changed the size of CNV legions, compared with their vehicle controls.

Conclusions : We did not confirm the anti-angiogenic activity of IL-18, in laser-induced CNV mice.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×